Clinical trial · Observational
Cardiac Toxicity in Medical Treatment of Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will describe the epidemiology including prognosis of heart failure related to treatment with anthracycline and trastuzumab for breast cancer. In a prospective study Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer patients scheduled for trastuzumab treatment at Odense University Hospital, will be offered advanced echocardiographic examination, test of bio-markers and genetic markers for the purpose of investigating if early identification of patients in particular risk of developing heart failure is feasible.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Heart Failure | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Global longitudinal strain by two dimentional speckle tracking.
- timeFrame
- Change in outcome from initiation of trastuzumab treatment and after 3,6, and 9 month.
- measure
- Ratio between the mitral E velocity and early diastolic maximum global strain rate (E/SRE).
- timeFrame
- Change in outcome from initiation of trastuzumab treatment and after 3,6, and 9 month.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of HER2 positive breast cancer * Adjuvant treatment with trastuzumab Exclusion Criteria: * Left ventricle ejection fraction (LVEF) \<50% * Chronic or persistent atrial fibrillation * History of moderate or severe valvular heart disease.
References
Publications (0)
Data not yet available